Search CommunityWalk:
Create_a_map_small
Mymaps_small



Blank

RegeneRx Biopharmaceuticals Inc

Address:
15245 Shady Grove Road
Suite 470
Rockville, MD 20850, USA
1-301-208-9191

Category: Biomaterials & Tissue Regeneration

Used in the following map:

Maryland Biotech Industry Map

RegeneRx Biopharmaceuticals Inc is a clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. It was founded in 1982 with a mission to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.

RegeneRx is developing products based on Thymosin beta 4 (T Beta 4). T Beta 4 is a naturally occurring peptide. It is found in high concentrations in blood platelets, wound fluid and other tissues in the body. T Beta 4 has been found to play an important role in protection, regeneration and remodeling of injured or damaged tissues. Its T Beta 4 involved in a wide variety of biological activities includes regulation of actin, epithelialization, angiogenesis, apoptosis and anti-inflammation.

RegeneRx's products include: RGN352 for the treatment of Acute Myocardial Infarction; RGN137, a topical gel formulation of the peptide Tbeta4, as a novel treatment to accelerate dermal wound healing; RGN-259, a Tbeta4-based sterile eye drop, as a novel treatment for corneal healing; and RGN-457 as a novel inhaled (via nebulization) treatment for cystic fibrosis and bronchiectasis.

RegeneRx research and development efforts are primarily focused on collaborating with major research institutions to expand its technology platform for manufacturing and formulation of its products, and the sponsorship of human clinical trials. The company has collaborations with National Heart, Lung, and Blood Institute (NHLBI), University of Maryland, National Institutes of Health, The US Department of Health and Human Services, Defiante Farmaceutica L.d.a., etc.